The Medicines New Zealand Code of Practice (Code) exists to ensure high standards of ethical and responsible promotion of prescription medicines in New Zealand, and wherever possible to exceed those required by law.

The Code represents an act of self-regulation and acceptance and observance of the Code is a condition of membership of Medicines New Zealand. Member companies must comply with both the letter and spirit of the Code.

Pharmaceutical companies that are not members of Medicines New Zealand are invited to accept and observe the Code and must comply with its provisions where required by the Advertising Standards Authority.

 

2019 UPDATE TO THE CODE OF PRACTICE

The Code of Practice is a living document reviewed every three years to ensure that it remains up-to-date, clear and easy to interpret. Edition 17 effective from 1 September 2019, is the latest edition of the Code.

Download a copy of the 17th Edition of the Code of Practice 

 

To ensure alignment with the latest iteration of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Code of Practice which was released after the publication of Edition 17 Medicines New Zealand's Code of Practice two Supplementary Guidance notes have been released. 

Download a copy of Supplementary Guidance note one (Effective 22 April 2021)

Download a copy of Supplementary Guidance note two (Effective 31 March 2022)

 

Please contact us for information about Code of Practice training.

Medicines New Zealand Guidelines for Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals

 

The Medicines New Zealand and New Zealand Medical Association (NZMA) Joint Transparency Initiative becomes effective on 1 January 2021. This initiative aims to promote public confidence in the biopharmaceutical industry through increasing transparency around the interactions between Healthcare Professionals and companies from the innovative medicines sector.

The cornerstone of the Transparency Initiative are the voluntary Guidelines For Disclosure Of Transfers Of Value From Pharmaceutical Companies To Healthcare Professionals which were developed by a joint Working Group composed of representatives from Medicines New Zealand’s Member Companies and the NZMA.

 

Click on the links below to review the Guidelines and also the accompanying Frequently Asked Questions resource.